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nine chondrocytes. By looking at cartilage proteins expression and
degradative enzymes activity, we hope to identify GDF-5 action on
OA cartilage homeostasis.
Methods: Human OA chondrocytes were isolated from patients
undergoing knee replacement. Canine OA chondrocytes were
generated from the Nuki-Pond dog model. After in vitro expansion,
chondrocytes were co-incubated with increasing concentrations of
rhGDF-5. Expression of selected markers of cartilage metabolism
(aggrecans, type-I and -II collagen, ADAMST-4 and -5) was ana-
lyzed at the mRNA and protein levels using qRT-PCR and western
blot respectively. Aggrecans degradation products, which reﬂect
the activity of aggrecanases, were also analyzed by western blot
following GDF-5 stimulation.
Results: Similar responses were recorded in human and canine
chondrocytes. Stimulation of human and canine OA chondrocytes
with rhGDF-5 led to a dose-dependent increase of aggrecans and
type II/type I collagen ratio, with a concomitant decrease in both
ADAMTS-4 and ADAMTS-5 mRNA expression. A similar action
for rhGDF-5 was observed for aggrecans and ADAMTS-4 and
ADAMTS-5 at the protein level. Finally, aggrecans degradation
products were also signiﬁcantly decreased in OA chondrocytes
following rhGDF-5 stimulation.
Conclusions: Interestingly, the addition of rhGDF-5 had a dual
effect on OA chondrocytes, increasing markers of anabolic ac-
tivity and decreasing catabolic enzymes expression and activity.
These results suggest a key role for GDF-5 in maintaining carti-
lage homeostasis, an action that could be loss in OA. Because
GDF-5 concentrations are constant in normal and OA cartilage,
interference with GDF-5 signalling may occur in OA, an anomaly
that appears to be recovered by the addition of rhGDF-5. Further
in vivo studies will evaluate the potential of GDF-5 as a disease
modifying drug in OA.
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Purpose: Extracellular matrix (ECM) degradation and formation
are closely linked and tightly regulated in order to maintain carti-
lage and bone homeostasis. In cartilage and bone, accumulation
of 4-hydroxynonenal (HNE), a product of lipid peroxidation (LPO),
undergoes considerable alterations in ECM structure and thereby
rendering it more prone to mechanical damage. This study aimed
to demonstrate that interaction between HNE-modiﬁed extracel-
lular matrix and chondrocytes or osteoblasts induced changes in
cell morphology and function of these cells.
Methods: Plates culture were coated with 0.1 mg/well type II
collagen (Col II) and then modiﬁed by increasing concentrations
of HNE (0.1 to 2 mM). Chondrocytes or osteoblasts where then
incubated for 48 hrs in appropriate culture medium. Cell viability
was evaluated by MTT test. The protein expression of adhe-
sion molecules such as integrin αVβ3 and inter-cellular adhesion
molecule-1 (ICAM-1) is performed by Western blot. The level of
matrix metalloproteinase-13 (MMP-13), prostaglandin 2 (PGE2)
and osteocalcin (OC) was determined by ELISA using commercial
kits. Alkaline phosphatase (ALPase) activity was measured as the
release of p-nitrophenol hydrolysed from p-nitrophenyl phosphate.
Results: After 48 hrs of incubation, the modiﬁcation of Col II with 2
mM HNE induces shape change of chondrocytes and osteoblasts
from elongated phenotype to rounded phenotype with a 10% de-
crease in cell viability. At a functional level, the modiﬁcation of Col
II with 0.1-0.5 mM HNE enhanced the production of integrin αVβ3,
ICAM-1, MMP-13 and PGE2 in chondrocytes, and OC release and
ALPase activity in osteoblasts. In contrast, the modiﬁcation of Col
II with 1 and 2 mM HNE reduced their production in both cell
types.
Conclusions: Our results showed that interaction between HNE-
modiﬁed Col II and chondrocytes or osteoblasts induced changes
in cell phenotype of chondrocytes/osteoblasts and modulate the
expression of catabolic and inﬂammatory factors. As described
previously by our laboratory, we suggest that accumulation of
HNE/Col II adducts in OA cartilage and bone may play a critical
role in OA pathogenesis
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Purpose: In vitro, it is known that high doses of recombinant
interleukin-1 (IL-1) causes rapid and extensive cartilage degrada-
tion characterized by loss of proteoglycan from tissue to surround-
ing culture medium. However, IL-1 is only one of several potentially
catabolic factors detected in synovial ﬂuid from osteoarthritic (OA)
joints, and has been shown to be present at much lower con-
centrations than those typically employed in vitro. Our goal was
to expose cartilage explants to levels of IL-1 similar to those we
measured in OA synovial ﬂuid, assess the loss of sulfated GAG
from the tissue, and determine the effect of IL-1 blockade using
IL-1 receptor antagonist (IL-1ra).
Methods: Levels of IL-1 were determined in synovial ﬂuid collected
from OA patients. Bovine articular cartilage was harvested from
the patellofemoral groove of 3 adult animals, and prepared as
full-thickness discs 6 mm in diameter. These cartilage explants
were equilibrated for 48 hours in medium (DMEM with 50 μg/mL
gentamicin), then transferred to culture wells containing fresh
medium supplemented with IL-1 alpha ranging from 5000 ng/mL
(often used for in vitro degradation studies) to more clinically-
relevant levels (200, 20, 16, 8, 4, 2, 1, 0.5, and 0 ng/mL), based
on measured levels from above. To assess the contribution of other
potential catabolic factors, some cultures were also supplemented
with 30 kDa N-terminal fragment of ﬁbronectin (Fn-f) at reported
physiologic concentration (0.8 μM). The effect of IL-1 blockade
was assessed by preincubating some cartilage samples with 1.4
nM IL-1ra for 2 hours before addition of IL-1 or Fn-f. After 4
days, culture media were collected and assayed for sulfated GAG
content by DMMB, normalized to initial tissue wet weight. GAG
distribution was also visualized in cartilage discs by safranin-O
staining.
Results: Incubation of cartilage with IL-1 gave a dose-dependent
decrease in sGAG release between 5000 and 20 pg/mL. The
GAG content of the culture medium was not different from control
explants (no IL-1) for the range 0.5-20 pg/mL IL-1. Similarly, there
was no difference in safranin-O histology in this dose range.
Addition of IL-1ra to the culture medium completely inhibited this
loss. However, when Fn-f was included in the culture medium,
GAG release was increased, and the additional degradation was
not able to be inhibited by IL-1ra.
Conclusions: In later-stage OA patients, we and others have
detected IL-1 at very low levels. Incubation of cartilage with IL-1
at these concentrations did not induce GAG release over that of
untreated cartilage explants. However, at least one other catabolic
factor, Fn-f, induced degradation at a more clinically-relevant con-
centration. It may be that in advanced stages of OA, the contribu-
tion of IL-1 to degradation is not as pronounced as that of other
catabolic factors. While IL-1 may be more involved in earlier OA,
